𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws

✍ Scribed by Matthew R. Stumpe; Rakesh K. Chandra; Furhan Yunus; Sandeep Samant

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
108 KB
Volume
31
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Intravenous bisphosphonate therapy has been used for treatment of benign and malignant bone diseases and has been linked to osteonecrosis of the jaws.

Methods

Records of 638 patients treated with intravenous bisphosphonates were reviewed. Drug used, number of infusions, dosing interval, dosage, duration, and occasion of osteonecrosis, diagnosed by history and physical examination, were analyzed.

Results

The overall incidence of osteonecrosis was 0.94% (6/638). No significant relationship was observed between the incidence of osteonecrosis and demographic parameters, primary tumor, cumulative drug dose, or dosing interval. However, patients who developed osteonecrosis had a significantly greater mean number of infusions (p = .016) and significantly greater mean hours of infusion time (p = .0036).

Conclusions

The findings suggest positive correlation between the development of osteonecrosis and drug exposure as measured by number of infusions and total infusion hours. However, the relatively low incidence of osteonecrosis precluded definition of a direct dose–response relationship. © 2008 Wiley Periodicals, Inc. Head Neck, 2009

📜 SIMILAR VOLUMES

Bisphosphonate-related osteonecrosis of
Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: A belgian case series
✍ Sven Saussez; Rokneddine Javadian; Chloé Hupin; Michèle Magremanne; Gilbert Chan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB 👁 1 views

## Abstract ## Objectives: Bisphosphonate‐related osteonecrosis of the jaw (BROJ) is a serious oral complication of bisphosphonate (BP) treatment involving the exposure of necrotic maxillary or mandibular bone. Our purpose is to describe the clinical presentation of 34 cases of BROJ and to identif

Factors influencing surgical treatment o
Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws
✍ Arno Wutzl; Sebastian Pohl; Irene Sulzbacher; Rudolf Seemann; Günter Lauer; Rolf 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 480 KB 👁 2 views

## Abstract ## Background Bisphosphonates are known to be associated with osteonecrosis of the jaw. We assess factors underlying the success of surgical treatment in patients with bisphosphonate‐related osteonecrosis of the jaw (BRONJ). ## Methods Fifty‐eight patients were investigated 6 months

Bisphosphonate-associated osteonecrosis
Bisphosphonate-associated osteonecrosis of the jaws: The limits of a conservative approach
✍ Giancarlo Tirelli; Matteo Biasotto; Silvia Chiandussi; Franca Dore; Elena De Nar 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 1 views

## Abstract ## Background. An increasing number of cases of osteonecrosis of the jaws (ONJ) in patients treated with bisphosphonates has been reported in the literature. ONJ significantly affects the patients' quality of life and its management is still extremely difficult. ## Methods. A woman w

Treatment results of bisphosphonate-rela
Treatment results of bisphosphonate-related osteonecrosis of the jaws
✍ Arno Wutzl; Edwin Biedermann; Felix Wanschitz; Rudolf Seemann; Clemens Klug; Arn 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB 👁 1 views

## Abstract ## Background. Osteonecrosis of the jaws occurs after the administration of bisphosphonates. An unequivocal treatment strategy is yet to be devised. We assess the treatment of patients with bisphosphonate‐related osteonecrosis of the jaws (BRONJ). ## Methods. The investigators studie

Treatment protocols of bisphosphonate-re
Treatment protocols of bisphosphonate-related osteonecrosis of the jaws
✍ Athanassios Kyrgidis; Georgios Koloutsos; Konstantinos Vahtsevanos 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB 👁 1 views

We read with great interest the article by Wutzl et al, 1 reporting a well-designed prospective study for the treatment of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in a cohort of multiple myeloma, breast cancer, and other diseases in patients. The authors duly report patients' under